Vedere Bio II

Vedere Bio II is a privately held, emerging biopharmaceutical company leveraging mutation agnostic technology and novel AAV capsids to restore vision in all patients with vision loss due to photoreceptor cell death. Comprised of a diverse team of pioneering scientists, Vedere Bio II is discovering and developing next generation ocular gene therapies to increase the quality of vision restoration and preservation for large, underserved indications.

Headquarters Cambridge, MA
Website www.vederebio.com​
Pipeline Status Preclinical
Twitter @VedereBio
LinkedIn Vedere Bio II